⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6852866 | 1.00 | — | — | |
| SCHEMBL1676681 | 1.00 | — | — | |
| SCHEMBL9100792 | 1.00 | — | — | |
| SCHEMBL6852863 | 1.00 | — | — | |
| SCHEMBL5312610 | 1.00 | — | — | |
| SCHEMBL6244444 | 0.75 | ALDH1A1 (0.39) | — | |
| SCHEMBL7610492 | 0.73 | ALDH1A1 (0.34) | — | |
| SCHEMBL1657591 | 0.73 | ALDH1A1 (0.36) | — | |
| SCHEMBL4957734 | 0.73 | ALDH1A1 (0.36) | — | |
| SCHEMBL1657594 | 0.73 | ALDH1A1 (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 129 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130046077-A1 | DOLASTATIN 15 DERIVATIVES | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2013-02-21 | — | — | US | claimed |
| US-8163698-B2 | Dolastatin 15 derivatives | ABBOTT GMBH & CO. KG (DE) | 2012-04-24 | — | — | US | claimed |
| JP-4508413-B2 | — | — | 2010-07-21 | — | — | JP | claimed |
| US-20100099843-A1 | DOLASTATIN 15 DERIVATIVES | ABBOTT GMBH & CO. KG (DE) | 2010-04-22 | — | — | US | claimed |
| US-7662786-B2 | oligopeptides; anticarcinogenic agent; good water solubility and cost effective; , B, D, E, F, G and K are alpha -amino acid residues, and s and r are each, independently, 0 or 1. L is a monovalent radical, such as,an amino group, an N-substituted amino group, a beta -hydroxylamino group, an alkoxy group | ABBOTT GMBH & CO. KG (DE) | 2010-02-16 | — | — | US | claimed |
| EP-1451209-A4 | TETRA-,PENTA-,HEXA- AND HEPTAPEPTIDES HAVING ANTIANGIOGENIC ACTIVITY | ABBOTT LAB (US) | 2009-06-03 | — | — | EP | claimed |
| EP-1450840-A4 | DI-, TRI,- AND TETRA-PEPTIDES HAVING ANTIANGIOGENIC ACTIVITY | ABBOTT LAB (US) | 2009-06-03 | — | — | EP | claimed |
| US-20080071062-A1 | TETRA-, PENTA-, HEXA- AND HEPTAPEPTIDES HAVING ANTIANGIOGENIC ACTIVITY | HAVIV FORTUNA | 2008-03-20 | — | — | US | claimed |
| EP-1461356-A4 | HEXA-, HEPTA-, AND OCTAPEPTIDES HAVING ANTIANGIOGENIC ACTIVITY | ABBOTT LAB (US) | 2007-12-12 | — | — | EP | claimed |
| US-20070167376-A1 | Hexa-, Hepta-, and Octapeptides Having Antiangiogenic Activity | HAVIV FORTUNA | 2007-07-19 | — | — | US | claimed |
| US-20010009901-A1 | Antineoplastic peptides | BASF AKTIENGESELLSCHAFT GERMANY | 2001-07-26 | — | — | US | claimed |
| WO-2001038397-A1 | N-ALKYLATED PEPTIDES HAVING ANTIANGIOGENIC ACTIVITY | ABBOTT LABORATORIES (US) | 2001-05-31 | — | — | WO | claimed |
| US-6143721-A | FOR TREATING CANCER IN MAMMALS | BASF AKTIENGESELLSCHAFT (DE) | 2000-11-07 | — | — | US | claimed |
| EP-0991658-A1 | DOLASTATIN 15 DERIVATIVES | BASF AKTIENGESELLSCHAFT (DE) | 2000-04-12 | — | — | EP | claimed |
| WO-1999003879-A1 | DOLASTATIN 15 DERIVATIVES | BASF AKTIENGESELLSCHAFT (DE) | 1999-01-28 | — | — | WO | claimed |
| EP-0866800-A2 | ANTINEOPLASTIC PEPTIDES | BASF AKTIENGESELLSCHAFT (DE) | 1998-09-30 | — | — | EP | claimed |
| WO-1997022621-A2 | ANTINEOPLASTIC PEPTIDES | BASF AKTIENGESELLSCHAFT (DE) | 1997-06-26 | — | — | WO | claimed |
| EP-0296122-B1 | CYCLOSPORINS AND THEIR USE AS PHARMACEUTICALS | SANDOZ AG (CH) | 1993-09-29 | — | — | EP | claimed |
| US-5182264-A | Angiotensin II receptor blockers as antiglaucoma agents | SCHERING CORPORATION (US) | 1993-01-26 | — | — | US | claimed |
| EP-0296122-A2 | Cyclosporins and their use as pharmaceuticals | SANDOZ AG (CH) | 1988-12-21 | — | — | EP | claimed |